Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Enrofloxacin (EFX) reacting with Ca(II) afforded a new complex, [Ca(EFX)(HO)] (EFX-Ca), which was structurally characterized both in solid and solution chemistry. and were tested to be the most sensitive strains for EFX-Ca. The LD value of EFX-Ca in mice was 7736 mg/kg, implying the coordination of EFX to Ca(II) effectively reduced its acute toxicity. EFX-Ca also decreased the plasma-binding rate and enhanced the drug distribution in rats along with longer elimination half-life. EFX-Ca also showed similar low in vivo acute toxicity and higher anti-inflammation induced by HO or CuSO in zebrafish, with reactive oxygen species (ROS)-related elimination. The therapeutic effects of EFX-Ca on two types (AA and 817) of -infected broilers were also better than those of EFX, with cure rates of 78% and 88%, respectively. EFX-Ca showed promise as a bio-safe metal-based veterinary drug with good efficacy and lower toxicity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878047 | PMC |
| http://dx.doi.org/10.3390/pharmaceutics14020249 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic models for radiation-induced complications after radiotherapy in head and neck cancer patients.
Cochrane Database Syst Rev
September 2025
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.
Background: Radiotherapy is the mainstay of treatment for head and neck cancer (HNC) but may induce various side effects on surrounding normal tissues. To reach an optimal balance between tumour control and toxicity prevention, normal tissue complication probability (NTCP) models have been reported to predict the risk of radiation-induced side effects in patients with HNC. However, the quality of study design, conduct, and analysis (i.
View Article and Find Full Text PDFAcute Pancreatitis Associated with Tacrolimus in A Lung Transplant Recipient: A Case Report and Review of Literature.
Eur J Case Rep Intern Med
July 2025
Intensive care unit, Clinical Hospital Sveti Duh, Zagreb, Croatia.
Background: Tacrolimus is a commonly used immunosuppressant with well-defined side effects, including hypertriglyceridemia and hyperglycaemia. However, acute pancreatitis is still not widely recognized as an adverse event related to tacrolimus.
Case Presentation: A 60-year-old male was admitted to the intensive care unit with symptoms and signs of acute pancreatitis.
Case Report: Effective methotrexate removal by combined hemodialysis and polymeric resin hemoadsorption.
Front Nephrol
August 2025
Department of Nephrology, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal.
Background: High-dose methotrexate (HDMTX) is central to treating primary central nervous system lymphoma but carries a risk of acute kidney injury (AKI), which can delay methotrexate (MTX) clearance and increase toxicity. Glucarpidase is the treatment of choice for MTX toxicity, but limited access in many countries may necessitate alternatives. We present the first reported adult case of combined high-flux hemodialysis (HFHD) and HA230 hemoadsorption for MTX clearance.
View Article and Find Full Text PDFWhen Pleasure Painted the Blood Blue: A Case of Popper-Induced Methemoglobinemia.
Cureus
August 2025
Acute Medicine, Weston General Hospital, University Hospitals Bristol and Weston, Weston-super-Mare, GBR.
Methemoglobinemia is an uncommon yet potentially life-threatening condition that results from the oxidation of iron from the ferrous (Fe²⁺) to the ferric (Fe³⁺) state, rendering hemoglobin unable to effectively transport oxygen. This translates into a state of functional hypoxia despite adequate arterial oxygen tension. Among the various causes of acquired methemoglobinemia, recreational inhalation of alkyl nitrites, widely known as "poppers," is a notable but underrecognized trigger.
View Article and Find Full Text PDFThe Impact of Cytoreduction on Blinatumomab Outcomes for Relapsed or Refractory B-ALL With High Disease Burden.
Am J Hematol
September 2025
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.
Blinatumomab is approved for the treatment of relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Studies have correlated pre-blinatumomab high disease burden (HDB) [> 50% bone marrow blasts (BMB)] with lower response rates and increased risk for toxicities, including cytokine release syndrome (CRS) and neurotoxicity (NT). While the administration of pre-blinatumomab cytoreductive therapy is an appealing approach, larger studies validating the beneficial effect of this strategy in patients with HDB are lacking.
View Article and Find Full Text PDF